ETRAElectra Therapeutics Inc.Signing up patients
Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 156 (planned)
- Started
- May 19, 2022
- Main results expected
- Mar 2028
- Fully finished
- Mar 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Number of Participant with Incidence of Treatment-Emergent Adverse Events (TEAEs) [Safety and tolerability]
Measured over: Up to Week 12
Part 2 (Cohort A): 56-day Survival Rate in Participants with mHLH and Have Lymphoma as the Cancer Trigger
Measured over: 56 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05416307 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC